<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">OTO</journal-id>
<journal-id journal-id-type="hwp">spoto</journal-id>
<journal-title>Otolaryngology–Head and Neck Surgery</journal-title>
<issn pub-type="ppub">0194-5998</issn>
<issn pub-type="epub">1097-6817</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0194599812436933</article-id>
<article-id pub-id-type="publisher-id">10.1177_0194599812436933</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Systematic Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Esophageal Reflux Disease Proton Pump Inhibitor Therapy Impact on Sleep Disturbance</article-title>
<subtitle>A Systematic Review</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Regenbogen</surname><given-names>Elliot</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0194599812436933">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Helkin</surname><given-names>Alex</given-names></name>
<xref ref-type="aff" rid="aff1-0194599812436933">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Georgopoulos</surname><given-names>Rachel</given-names></name>
<xref ref-type="aff" rid="aff1-0194599812436933">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Vasu</surname><given-names>Tajender</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-0194599812436933">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Shroyer</surname><given-names>A. Laurie W.</given-names></name>
<degrees>PhD, MSHA</degrees>
<xref ref-type="aff" rid="aff3-0194599812436933">3</xref>
</contrib>
</contrib-group>
<aff id="aff1-0194599812436933"><label>1</label>Division of Otolaryngology Head and Neck Surgery, Stony Brook University Medical Center, Stony Brook, New York, USA</aff>
<aff id="aff2-0194599812436933"><label>2</label>Division of Pulmonary, Critical Care and Sleep Medicine, Stony Brook University Medical Center, Stony Brook, New York, USA</aff>
<aff id="aff3-0194599812436933"><label>3</label>Department of Surgery, Stony Brook University School of Medicine, Stony Brook, New York, USA</aff>
<author-notes>
<corresp id="corresp1-0194599812436933">Elliot Regenbogen, MD, Division of Otolaryngology Head and Neck Surgery, Stony Brook University Medical Center, HSC T19-065, Stony Brook, NY 11794-8191, USA Email: <email>elliot.regenbogen@sbumed.org</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2012</year>
</pub-date>
<volume>146</volume>
<issue>4</issue>
<fpage>524</fpage>
<lpage>532</lpage>
<history>
<date date-type="received">
<day>31</day>
<month>10</month>
<year>2011</year>
</date>
<date date-type="rev-recd">
<day>5</day>
<month>12</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>6</day>
<month>1</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© American Academy of Otolaryngology—Head and Neck Surgery Foundation 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">Official journal of the American Academy of Otolaryngology–Head and Neck Surgery Foundation</copyright-holder>
</permissions>
<abstract>
<p><italic>Objective</italic>. To perform a systematic literature review that evaluates the impact of proton pump inhibitor treatment of gastroesophageal reflux disease on sleep disturbance–related outcomes.</p>
<p><italic>Data Sources</italic>. PubMed, Web of Science, and Cochrane databases were searched from 1989 (when omeprazole became available) to present; additional references gleaned from citations.</p>
<p><italic>Review Methods</italic>. The search strategy identified all randomized placebo-controlled clinical trials published in English; both proton pump inhibitor use and outcome measures of sleep disturbance were reported for esophageal reflux disease patients. Using a preestablished systematic review protocol and data extraction format, 4 coauthors independently reviewed all articles.</p>
<p><italic>Results</italic>. The original search identified 20 articles; 9 were not directly relevant, and 3 were not placebo controlled. Sample sizes varied from 15 to 642; mean age was 47.4 ± 4.56 years; mean body mass index was 29.4 ± 2.9; the proportion of women varied widely across studies. Esomeprazole was studied most frequently. More than 50% of publications permitted rescue antacids. Two studies reported polysomnography outcomes, without statistically significant improvement. All studies reported non-polysomnography outcomes; 7 identified statistically significant improvements demonstrating drug treatment superiority over placebo.</p>
<p><italic>Conclusion</italic>. The existing evidence supports the use of proton pump inhibitors as a treatment for esophageal reflux disease to improve quality-of-life sleep disturbance–related outcomes. Given the wide variability in proton pump inhibitor treatments and sleep disturbance–related outcomes reported, however, study-specific results cannot be directly compared or aggregated. This conclusion appears robust not only for 7 of 8 studies included but also for the 3 highest quality studies.</p>
</abstract>
<kwd-group>
<kwd>sleep disturbance</kwd>
<kwd>proton pump inhibitor</kwd>
<kwd>gastroesophageal reflux disease</kwd>
<kwd>systematic review</kwd>
<kwd>outcomes assessment</kwd>
<kwd>sleep apnea syndromes</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>According to data from 2000, gastroesophageal reflux disease (GERD) was responsible for $9.8 billion in both direct and indirect costs. Pharmacotherapy for GERD includes generic, brand-name, and over-the-counter drugs that rank near the top of their respective lists with regard to expenditure.<sup><xref ref-type="bibr" rid="bibr1-0194599812436933">1</xref></sup> Since the introduction of omeprazole in 1989 and the subsequent development and release of lansoprazole, rabeprazole, pantoprazole, and esomeprazole, the proton pump inhibitors (PPIs) have been proven to be superior in the treatment and symptomatic remission of nonerosive reflux disease and erosive esophagitis compared with histamine-2 receptor antagonists in numerous randomized, controlled trials.<sup><xref ref-type="bibr" rid="bibr2-0194599812436933">2</xref></sup></p>
<p>In a large national survey evaluating the presence of nocturnal GERD (n-GERD) and its effect on quality of life, 10% of respondents reported symptoms of n-GERD.<sup><xref ref-type="bibr" rid="bibr3-0194599812436933">3</xref></sup> This finding is in sharp contrast to the prevalence of n-GERD in patients with obstructive sleep apnea (OSA). The frequency of n-GERD in patients with OSA ranges from 54% to 76%.<sup><xref ref-type="bibr" rid="bibr4-0194599812436933">4</xref></sup> In a recent prospective study of 331 patients with OSA, n-GERD was present in 62% before the start of continuous positive airway pressure (CPAP) treatment.<sup><xref ref-type="bibr" rid="bibr4-0194599812436933">4</xref></sup> Epidemiological studies have demonstrated that the frequency of nighttime heartburn is a very significant risk factor for adenocarcinoma of the esophagus, and patients with Barrett disease have been shown to repeat episodes of sleep-related GERD.<sup><xref ref-type="bibr" rid="bibr5-0194599812436933">5</xref>,<xref ref-type="bibr" rid="bibr6-0194599812436933">6</xref></sup> In many patients suffering from GERD and its complications, reported health-related quality of life is lower than in patients who have untreated angina pectoris, chronic heart failure, or diabetes mellitus.<sup><xref ref-type="bibr" rid="bibr7-0194599812436933">7</xref></sup></p>
<p>For several reasons, sleep is potentially conducive to the GERD events. Antireflux mechanisms such as swallowing rate, upper and lower esophageal sphincter pressure, gastric emptying, and the awareness of heartburn have all been found to be depressed during sleep.<sup><xref ref-type="bibr" rid="bibr3-0194599812436933">3</xref>,<xref ref-type="bibr" rid="bibr8-0194599812436933">8</xref>-<xref ref-type="bibr" rid="bibr12-0194599812436933">12</xref></sup> Also, while recumbent, the force of gravity encourages the flow of gastric content toward the esophagus.<sup><xref ref-type="bibr" rid="bibr8-0194599812436933">8</xref></sup> Studies measuring esophageal pH and polysomnography in patients with sleep apnea have shown that some reflux events coincide with arousals.<sup><xref ref-type="bibr" rid="bibr12-0194599812436933">12</xref></sup> However, it was also found that not all apneic periods coincide with reflux events.</p>
<p>Earlier investigations focusing on the relationship between sleep-related breathing disorders and GERD have indicated the adverse effect of nocturnal reflux events on the sleep structure.<sup><xref ref-type="bibr" rid="bibr9-0194599812436933">9</xref>,<xref ref-type="bibr" rid="bibr10-0194599812436933">10</xref></sup> Furthermore, some epidemiological studies have suggested a relationship between GERD and daytime sleepiness.<sup><xref ref-type="bibr" rid="bibr11-0194599812436933">11</xref>,<xref ref-type="bibr" rid="bibr13-0194599812436933">13</xref>-<xref ref-type="bibr" rid="bibr15-0194599812436933">15</xref></sup> The ProGERD study in 2003 found that effective treatment of GERD resulted in a statistically significant improvement of patients’ perceptions of sleep disorders during treatment with esomeprazole within 2 weeks.<sup><xref ref-type="bibr" rid="bibr16-0194599812436933">16</xref></sup> The results of a Gallup telephone survey—conducted on behalf of the American Gastroenterological Association—have shown that the nocturnal heartburn and the regurgitation of gastric content caused frequent awakenings and sleep disturbances, which could affect daytime performance and the quality of life.<sup><xref ref-type="bibr" rid="bibr17-0194599812436933">17</xref></sup> Therefore, it appears that nighttime reflux could have a considerable impact on the quality of sleep and a significant role in the development of restless sleep experienced widely by the patients.</p>
<p>Although there are established criteria for treating GERD symptoms, there are no well-established clinical guidelines or a widely accepted national professional society consensus opinion as to how best to treat GERD patients with regard to associated sleep disturbance–related issues and outcomes. The goal for this systematic review (SR), therefore, was to identify patterns in PPI treatments emerging across the relevant randomized controlled trial (RCT) publications’ findings. Specifically, the purpose of this SR was to evaluate the impact of PPI treatment on sleep disturbance–related outcomes in patients with sleep disturbance due to nocturnal GERD and also patients with GERD who have sleep-disordered breathing.</p>
<sec id="section1-0194599812436933" sec-type="methods">
<title>Methods</title>
<sec id="section2-0194599812436933">
<title>Eligibility Criteria</title>
<p>For potential consideration in this SR, all relevant RCTs were identified. Relevance was defined as the study being conducted as a placebo-controlled RCT where both the use of a PPI and sleep-related outcomes were reported. These outcome measures could include polysomnography (PSG) and/or non-polysomnography (non-PSG) measures of sleep disturbance. Per preestablished protocol inclusion/exclusion criteria, all eligible abstracts identified were carefully reviewed. Full-text versions were ordered for those studies that met inclusion and exclusion criteria. Final selections of articles to be reviewed were limited to randomized clinical trials, placebo controlled, English language, and human subjects.</p>
</sec>
<sec id="section3-0194599812436933">
<title>Information Sources and Search Strategy</title>
<p>A systematic literature review (SR) was performed in PubMed, Web of Science, and Cochrane Library from 1989 (when omeprazole became available) to October 2011. Additional relevant publications were identified based on the articles’ citations.</p>
</sec>
<sec id="section4-0194599812436933">
<title>Data Extraction</title>
<p>For each study, the following data were extracted if available: first author’s last name, publication year, journal, journal impact factor, purpose of study, drug used, dose, number of patients beginning study, number of patients ending study, number of male and female patients, mean age, age range, body mass index (BMI), subject inclusion criteria, subject exclusion criteria, and a listing of pre- and posttreatment GERD measures. Pre- and posttreatment polysomnography measures were captured: apnea hypopnea index (AHI), apnea index, hypopnea index, respiratory disturbance index (RDI), minimum SaO<sub>2</sub> (%), arousal index, arousal number (if arousal index not calculated), total sleep time (TST), sleep onset latency (SOL), sleep efficiency, %sleep stage 1, %sleep stage 2, %sleep stage 3/4, rapid eye movement (REM) sleep time, REM-onset latency, total awake time, number of arousals preceded by gastroesophageal reflux, number of awakenings preceded by gastroesophageal reflux, and any other measures noted. Pre- and posttreatment non-polysomnography measures were captured: Epworth Sleepiness Scale (ESS), Pittsburgh Sleep Quality Index (PSQI), Functional Outcomes of Sleepiness Questionnaire (FOSQ), diary used, visual analog scale (VAS) for subjective sleep quality, reaction time, sleep scale, Impact on Daily Activity Scale (IDAS), Psychological General Well Being (PGWB), Quality of Life in Reflux and Dyspepsia (QOLRAD), Work Productivity and Activity Impairment (WPAI), snoring level, SF-36, actigraphy, and any other sleep-related outcomes documented. To assess for a potential bias, drug company sponsorship (if this information was provided) was also captured.</p>
</sec>
<sec id="section5-0194599812436933">
<title>Primary Outcomes</title>
<p>To identify an impact of PPI for patients with esophageal reflux disease, the primary SR outcomes evaluated were measures of sleep time and quality. These outcomes included polysomnography-based measures (such as AHI) and non-polysomnography measures (such as the PSQI, WPAI, ESS, and other health-related quality-of-life [HRQOL] questionnaires).</p>
</sec>
<sec id="section6-0194599812436933">
<title>Assessment of Publication Quality</title>
<p>On the basis of the data abstracted using a standardized data capture format and definitions, all 4 reviewers independently graded the quality of each study using the Jadad scale<sup><xref ref-type="bibr" rid="bibr18-0194599812436933">18</xref></sup> and assigned an Oxford level of evidence.<sup><xref ref-type="bibr" rid="bibr19-0194599812436933">19</xref></sup> For the primary data captured and the publication quality assessments, the results from all 4 raters were compared. Any disagreements among raters were decided by means of discussion with a consensus decision.</p>
</sec>
</sec>
<sec id="section7-0194599812436933" sec-type="results">
<title>Results</title>
<sec id="section8-0194599812436933">
<title>Eligible Trials</title>
<p>For the period from January 1989 to September 2011, the original search strategy returned 20 references. Review of the abstracts initially excluded 9 articles that were not directly relevant to the research question raised. In total, 11 papers were reviewed, but 3 subsequently were excluded (as these RCTs were not placebo controlled). A PRISMA flowchart for the study search and selection process is shown in <xref ref-type="fig" rid="fig1-0194599812436933"><bold>Figure 1</bold></xref>.</p>
<fig id="fig1-0194599812436933" position="float">
<label>Figure 1.</label>
<caption><p>PRISMA flowchart for the study search and selection process. GERD, gastroesophageal reflux disease; PPI, proton pump inhibitor; RCT, randomized controlled trial.</p></caption>
<graphic xlink:href="10.1177_0194599812436933-fig1.tif"/>
</fig>
<p>A total of 8 randomized placebo-controlled trials published from 2004 to 2011 were eligible for analysis. The objectives for each study and inclusion criteria are listed in <xref ref-type="table" rid="table1-0194599812436933"><bold>Table 1</bold></xref>. Two of the studies included sleep-disordered breathing as an objective and were the only 2 of 8 studies that used polysomnography measures as part of their study-specific inclusion criteria; only 1 directly measured esophageal pH, and the remaining studies used history and/or questionnaire. Five of 8 studies allowed use of additional rescue antacids; 2 also allowed continued use of other sleep medications if it had been consistent (≥3 months prior to the study). Six of the 8 studies had stated sponsorship from pharmaceutical companies; 2 studies did not identify any financial sponsors.</p>
<table-wrap id="table1-0194599812436933" position="float">
<label>Table 1.</label>
<caption><p>Systematic Literature Search, 1989 to 2011</p></caption>
<graphic alternate-form-of="table1-0194599812436933" xlink:href="10.1177_0194599812436933-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th/>
<th/>
<th align="center" colspan="2">Inclusion Criteria</th>
<th/>
<th/>
</tr>
<tr>
<th align="left">Primary Author</th>
<th align="center">Purpose</th>
<th align="center">Sleep</th>
<th align="center">Reflux Disease</th>
<th align="center">Additional Medications</th>
<th align="center">Funding/Sponsorship</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bortolotti 2006<sup><xref ref-type="bibr" rid="bibr31-0194599812436933">31</xref>,<xref ref-type="table-fn" rid="table-fn2-0194599812436933">a</xref></sup>
</td>
<td>Investigated whether the treatment of gastroesophageal reflux with PPI is able to decrease apnea attacks</td>
<td>PSG</td>
<td>pH</td>
<td align="center">—</td>
<td>None identified</td>
</tr>
<tr>
<td>Fass 2011<sup><xref ref-type="bibr" rid="bibr23-0194599812436933">23</xref></sup>
</td>
<td>Efficacy of PPI therapy in relieving nocturnal heartburn, GERD-related sleep disturbances, improving work productivity, decreasing nocturnal symptom severity</td>
<td>Non-PSG</td>
<td>History of nocturnal heartburn</td>
<td>Aluminum/magnesium hydroxide (Gelusil)</td>
<td>Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Johnson 2005<sup><xref ref-type="bibr" rid="bibr24-0194599812436933">24</xref></sup>
</td>
<td>Effects of PPI therapy on nighttime heartburn, GERD sleep disturbances, sleep quality, work productivity, regular activities</td>
<td>Non-PSG</td>
<td>History of heartburn or acid regurgitation; any history of EE</td>
<td>Sleep medication, antihistamine, benzodiazepine, antianxiety medication, Gelusil</td>
<td>Astra Zeneca</td>
</tr>
<tr>
<td>Johnson 2010<sup><xref ref-type="bibr" rid="bibr25-0194599812436933">25</xref></sup>
</td>
<td>Efficacy of PPI therapy on GERD-related nighttime heartburn and associated sleep disturbances</td>
<td>Non-PSG</td>
<td>History of heartburn or acid regurgitation; any history of EE; nighttime GERD symptoms</td>
<td>Sleep medication, Gelusil</td>
<td>Astra Zeneca</td>
</tr>
<tr>
<td>Orr 2005<sup><xref ref-type="bibr" rid="bibr26-0194599812436933">26</xref></sup>
</td>
<td>Whether PPI would improve objective and subjective measures of sleep</td>
<td>Non-PSG</td>
<td>History of heartburn, which strongly suggested significant GERD</td>
<td>H2-blockers, antacids but not within 24 hours of their pH study</td>
<td>Astra Zeneca</td>
</tr>
<tr>
<td>Orr 2007<sup><xref ref-type="bibr" rid="bibr20-0194599812436933">20</xref></sup>
</td>
<td>Occurrence of acidic and nonacidic reflux during sleep under PPI treatment</td>
<td>No criteria defined</td>
<td>History of heartburn</td>
<td align="center">—</td>
<td>Janssen Pharmaceuticals</td>
</tr>
<tr>
<td>Suurna 2008<sup><xref ref-type="bibr" rid="bibr21-0194599812436933">21</xref>,<xref ref-type="table-fn" rid="table-fn2-0194599812436933">a</xref></sup>
</td>
<td>Efficacy of PPI therapy for daytime, somnolence, vigilance, QOL in patients with obstructive sleep-disordered breathing</td>
<td>PSG, non-PSG</td>
<td>Symptoms of GERD; GERD questionnaire</td>
<td align="center">—</td>
<td>TAP Pharmaceutical/Takeda Pharmaceuticals</td>
</tr>
<tr>
<td>Yi 2008<sup><xref ref-type="bibr" rid="bibr27-0194599812436933">27</xref></sup>
</td>
<td>Whether PPI would change autonomic function and subjective sleep function in patient with erosive esophagitis</td>
<td>No criteria defined</td>
<td>Symptoms of GERD; EE</td>
<td>Antacid</td>
<td>None identified</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0194599812436933">
<p>Abbreviations: EE, erosive esophagitis; GERD, gastroesophageal reflux disease; PPI, proton pump inhibitor; PSG, polysomnography; QOL, quality of life; —, not identified.</p>
</fn>
<fn id="table-fn2-0194599812436933">
<label>a</label>
<p>Study objective includes sleep-disordered breathing.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p><xref ref-type="table" rid="table2-0194599812436933"><bold>Table 2</bold></xref> reports study demographics. The number of subjects analyzed varied from 15 to 642. The mean of the averages reported for patient age (for the 7 studies reporting mean age) was 47.4 ± 4.56 years; 1 study listed an age range only. The average proportion of female participants was 56%. Five of the 8 studies reported BMI; the mean of the average study-specific BMI was 29.4 ± 2.9. Although sleep-disordered breathing was studied in 2 studies, it was specifically recognized as an exclusion criterion in only 2 of the remaining 6 studies.</p>
<table-wrap id="table2-0194599812436933" position="float">
<label>Table 2.</label>
<caption><p>Study Demographics</p></caption>
<graphic alternate-form-of="table2-0194599812436933" xlink:href="10.1177_0194599812436933-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Primary Author</th>
<th align="center">No. Subjects Analyzed</th>
<th align="center">Age, y, Mean</th>
<th align="center">Female, %</th>
<th align="center">BMI, Mean</th>
<th align="center">SDB Patients Excluded</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bortolotti 2006<sup><xref ref-type="bibr" rid="bibr31-0194599812436933">31</xref>,<xref ref-type="table-fn" rid="table-fn4-0194599812436933">a</xref></sup>
</td>
<td>20</td>
<td>55<sup><xref ref-type="table-fn" rid="table-fn5-0194599812436933">b</xref></sup>
</td>
<td>15</td>
<td>30<sup><xref ref-type="table-fn" rid="table-fn5-0194599812436933">b</xref></sup>
</td>
<td>No</td>
</tr>
<tr>
<td>Fass 2011<sup><xref ref-type="bibr" rid="bibr23-0194599812436933">23</xref></sup>
</td>
<td>293</td>
<td>44 ± 12</td>
<td>67</td>
<td>30 ± 7</td>
<td>No</td>
</tr>
<tr>
<td>Johnson 2005<sup><xref ref-type="bibr" rid="bibr24-0194599812436933">24</xref></sup>
</td>
<td>642</td>
<td>47<sup><xref ref-type="table-fn" rid="table-fn5-0194599812436933">b</xref></sup>
</td>
<td>60</td>
<td>—</td>
<td>Yes</td>
</tr>
<tr>
<td>Johnson 2010<sup><xref ref-type="bibr" rid="bibr25-0194599812436933">25</xref></sup>
</td>
<td>262</td>
<td>47<sup>b</sup>
</td>
<td>66</td>
<td>31<sup><xref ref-type="table-fn" rid="table-fn5-0194599812436933">b</xref></sup>
</td>
<td>No</td>
</tr>
<tr>
<td>Orr 2005<sup><xref ref-type="bibr" rid="bibr26-0194599812436933">26</xref></sup>
</td>
<td>28</td>
<td>45</td>
<td>43</td>
<td>—</td>
<td>Yes</td>
</tr>
<tr>
<td>Orr 2007<sup><xref ref-type="bibr" rid="bibr20-0194599812436933">20</xref></sup>
</td>
<td>15</td>
<td>45</td>
<td>67</td>
<td>—</td>
<td>No</td>
</tr>
<tr>
<td>Suurna 2008<sup><xref ref-type="bibr" rid="bibr21-0194599812436933">21</xref>,<xref ref-type="table-fn" rid="table-fn4-0194599812436933">a</xref></sup>
</td>
<td>57</td>
<td>51 ± 12</td>
<td>58</td>
<td>31 ± 7</td>
<td>No</td>
</tr>
<tr>
<td>Yi 2008<sup><xref ref-type="bibr" rid="bibr27-0194599812436933">27</xref></sup>
</td>
<td>28</td>
<td>22-55</td>
<td>71</td>
<td>24</td>
<td>No</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0194599812436933">
<p>Abbreviations: BMI, body mass index; SDB, sleep-disordered breathing; —, not provided.</p>
</fn>
<fn id="table-fn4-0194599812436933">
<label>a</label>
<p>Study objective includes sleep-disordered breathing</p>
</fn>
<fn id="table-fn5-0194599812436933">
<label>b</label>
<p>Weighted mean.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Esomeprazole was used in half of the studies (<xref ref-type="table" rid="table3-0194599812436933"><bold>Table 3</bold></xref>). The 4 studies that used esomeprazole reported the dosages ranging from 20 to 40 mg, all using once-daily dosing except Orr et al,<sup><xref ref-type="bibr" rid="bibr20-0194599812436933">20</xref></sup> who used twice-daily dosing. Each of the remaining studies used a different PPI dosed once or twice daily. Seven of the studies that chose once-daily dosing specified morning dosing; Suurna et al<sup><xref ref-type="bibr" rid="bibr21-0194599812436933">21</xref></sup> did not specify the time drug/placebo was given.</p>
<table-wrap id="table3-0194599812436933" position="float">
<label>Table 3.</label>
<caption><p>Proton Pump Inhibitor, Dose, Use of Rescue Antacid, and Outcome Measures Used</p></caption>
<graphic alternate-form-of="table3-0194599812436933" xlink:href="10.1177_0194599812436933-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Primary Author</th>
<th align="center">Drug</th>
<th align="center">Dose/Frequency/ Timing</th>
<th align="center">Rescue Antacid</th>
<th align="center">PSG</th>
<th align="center">Non-PSG</th>
<th align="center">pH</th>
<th align="center">Non-pH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bortolotti 2006<sup><xref ref-type="bibr" rid="bibr31-0194599812436933">31</xref>,<xref ref-type="table-fn" rid="table-fn7-0194599812436933">a</xref></sup>
</td>
<td>Omeprazole</td>
<td>20 mg/bid/<sc>am</sc>, <sc>pm</sc></td>
<td align="center">—</td>
<td align="center">—</td>
<td>+</td>
<td align="center">—</td>
<td align="center">—</td>
</tr>
<tr>
<td>Fass 2011<sup><xref ref-type="bibr" rid="bibr23-0194599812436933">23</xref></sup>
</td>
<td>Dexlansoprazole</td>
<td>30 mg/qd/<sc>am</sc></td>
<td>+</td>
<td align="center">—</td>
<td>+</td>
<td align="center">—</td>
<td>+</td>
</tr>
<tr>
<td>Johnson 2005<sup><xref ref-type="bibr" rid="bibr24-0194599812436933">24</xref></sup>
</td>
<td>Esomeprazole</td>
<td>40, 20 mg/qd/<sc>am</sc></td>
<td>+</td>
<td align="center">—</td>
<td>+</td>
<td align="center">—</td>
<td>+</td>
</tr>
<tr>
<td>Johnson 2010<sup><xref ref-type="bibr" rid="bibr25-0194599812436933">25</xref></sup>
</td>
<td>Esomeprazole</td>
<td>20 mg/qd/<sc>am</sc></td>
<td>+</td>
<td align="center">—</td>
<td>+</td>
<td align="center">—</td>
<td>+</td>
</tr>
<tr>
<td>Orr 2005<sup><xref ref-type="bibr" rid="bibr26-0194599812436933">26</xref></sup>
</td>
<td>Rabeprazole</td>
<td>20 mg/bid/<sc>am</sc>, <sc>pm</sc></td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Orr 2007<sup><xref ref-type="bibr" rid="bibr20-0194599812436933">20</xref></sup>
</td>
<td>Esomeprazole</td>
<td>40 mg/bid/<sc>am</sc>, <sc>pm</sc></td>
<td align="center">—</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Suurna 2008<sup><xref ref-type="bibr" rid="bibr21-0194599812436933">21</xref>,<xref ref-type="table-fn" rid="table-fn7-0194599812436933">a</xref></sup>
</td>
<td>Pantoprazole</td>
<td>40 mg/qd/not stated</td>
<td align="center">—</td>
<td align="center">—</td>
<td>+</td>
<td align="center">—</td>
<td>+</td>
</tr>
<tr>
<td>Yi 2008<sup><xref ref-type="bibr" rid="bibr27-0194599812436933">27</xref></sup>
</td>
<td>Esomeprazole</td>
<td>40 mg/qd/<sc>am</sc></td>
<td>+</td>
<td align="center">—</td>
<td>+</td>
<td align="center">—</td>
<td>+</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn6-0194599812436933">
<p>Abbreviation: PSG, polysomnography; —, not provided.</p>
</fn>
<fn id="table-fn7-0194599812436933">
<label>a</label>
<p>Study objective includes sleep-disordered breathing.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Outcomes selected are summarized in <xref ref-type="table" rid="table3-0194599812436933"><bold>Table 3</bold></xref>. With regard to GERD, 2 studies reported measures of pH, 6 reported non-pH measures (such as HRQOL surveys), and 1 did not report GERD outcomes. Two of 8 studies used polysomnography metrics as an outcome measure; all 8 used non-polysomnography measures.</p>
</sec>
<sec id="section9-0194599812436933">
<title>Polysomnography Results</title>
<p>For the 2 studies that used polysomnography as an outcome measure, results are shown in <xref ref-type="table" rid="table4-0194599812436933"><bold>Table 4</bold></xref>. Apnea hypopnea index was not reported for either study. None of the 5 measures looked at between the 2 studies (total sleep time, sleep onset latency, sleep efficiency, arousal per hour, or REM measures) showed a statistically significant difference (at the <italic>P</italic> &lt; .05 level) between placebo and drug groups.</p>
<table-wrap id="table4-0194599812436933" position="float">
<label>Table 4.</label>
<caption><p>Polysomnography Outcomes</p></caption>
<graphic alternate-form-of="table4-0194599812436933" xlink:href="10.1177_0194599812436933-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Primary Author</th>
<th align="center">Drug</th>
<th align="center">Interval to Outcome, wk</th>
<th align="center">TST, min</th>
<th align="center">SOL, min</th>
<th align="center">Sleep Efficiency, %</th>
<th align="center">Arousal per Hour</th>
<th align="center">REM Measures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Orr 2005<sup><xref ref-type="bibr" rid="bibr26-0194599812436933">26</xref></sup>
</td>
<td>Rabeprazole 20 mg</td>
<td>1</td>
<td align="center">—</td>
<td>18.0 (D)<break/>18.0 (P)<break/><italic>P</italic> = <italic>NS</italic>
</td>
<td>86.1 ± 1.8 (D)<break/>83.6 ± 2.7 (P)<break/><italic>P</italic> = <italic>NS</italic>
</td>
<td>13.6 ± 1.7 (D)<break/>14.5 ± 2.3 (P)<break/><italic>P</italic> = <italic>NS</italic>
</td>
<td>%stage 3+4: 11.0 ± 1.4 (D), 11.6 ± 1.4 (P), <italic>P</italic> = <italic>NS</italic>
<break/>%REM: 18.9 ± 1.6 (D), 20.1 ± 1.2 (P), <italic>P</italic> = <italic>NS</italic>
</td>
</tr>
<tr>
<td>Orr 2007<sup><xref ref-type="bibr" rid="bibr20-0194599812436933">20</xref></sup>
</td>
<td>Esomeprazole 40 mg</td>
<td>1</td>
<td>342.6 ± 51.9 (D)<break/>340.4 ± 41.6 (P)<break/><italic>P</italic> = <italic>NS</italic>
</td>
<td>14.7 ± 11.6 (D)<break/>21.3 ± 23.2 (P)<break/><italic>P</italic> = <italic>NS</italic>
</td>
<td>80.1±10.5(D)<break/>82.1±9.9(P)<break/><italic>P</italic> = <italic>NS</italic>
</td>
<td align="center">—</td>
<td align="center">—</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn8-0194599812436933">
<p>Abbreviations: D, drug; <italic>NS</italic>, not significant; P, placebo; REM, rapid eye movement; SOL, sleep onset latency; TST, total sleep time; —, not provided.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section10-0194599812436933">
<title>Non-Polysomnography Results</title>
<p>The PSQI was used in 4 studies as an outcome measure, and the outcomes are reported in <xref ref-type="table" rid="table5-0194599812436933"><bold>Table 5</bold></xref>. The PSQI is a 19-item validated questionnaire completed by patients regarding the previous 1-month period. Items are grouped into 7 component scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. Each component score is weighted equally on a 0 to 3 scale, with 3 representing the worse effect, then summed to yield a global PSQI score, which could range from 0 to 21. Patients with a global score <italic>&gt;</italic>5 are considered to have poor sleep quality.<sup><xref ref-type="bibr" rid="bibr22-0194599812436933">22</xref></sup> The reviewed studies vary in terms of drug selected, dosing, and duration of treatment prior to outcome measured. Each of these 4 studies demonstrated a significant difference in terms of change (improvement) from baseline comparing drug with the placebo group. Fass et al<sup><xref ref-type="bibr" rid="bibr23-0194599812436933">23</xref></sup> and Johnson et al<sup><xref ref-type="bibr" rid="bibr24-0194599812436933">24</xref></sup> report that the PSQI at 4 weeks remained &gt;5.</p>
<table-wrap id="table5-0194599812436933" position="float">
<label>Table 5.</label>
<caption><p>Non-Polysomnography, Pittsburgh Sleep Quality Index</p></caption>
<graphic alternate-form-of="table5-0194599812436933" xlink:href="10.1177_0194599812436933-table5.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Primary Author</th>
<th align="center">Drug</th>
<th align="center">Baseline, Mean (SD)</th>
<th align="center">Interval to Outcome, wk</th>
<th align="center">Outcome, Mean (SD)</th>
<th align="center">Change from Baseline, Mean (SD)</th>
<th align="center"><italic>P</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fass 2011<sup><xref ref-type="bibr" rid="bibr23-0194599812436933">23</xref></sup>
</td>
<td>Dexlansoprazole 30 mg</td>
<td>9.3 (3.6)</td>
<td>4</td>
<td/>
<td>−2.7 (3.1)</td>
<td>.001</td>
</tr>
<tr>
<td/>
<td>Placebo</td>
<td>8.9 (3.6)</td>
<td>4</td>
<td/>
<td>−1.4 (3.2)</td>
<td/>
</tr>
<tr>
<td>Johnson 2005<sup><xref ref-type="bibr" rid="bibr24-0194599812436933">24</xref></sup>
</td>
<td>Esomeprazole 40 mg</td>
<td>9.5 (4.1)</td>
<td>4</td>
<td>6.0 (3.8)</td>
<td>−3.5 (3.6)</td>
<td>&lt;.001 vs placebo</td>
</tr>
<tr>
<td/>
<td>Esomeprazole 20 mg</td>
<td>9.6 (3.9)</td>
<td>4</td>
<td>5.8 (4.0)</td>
<td>−3.8 (3.8)</td>
<td/>
</tr>
<tr>
<td/>
<td>Placebo</td>
<td>9.6 (3.8)</td>
<td>4</td>
<td>7.5 (4.0)</td>
<td>−2.0 (3.7)</td>
<td/>
</tr>
<tr>
<td>Johnson 2010<sup><xref ref-type="bibr" rid="bibr25-0194599812436933">25</xref></sup>
</td>
<td>Esomeprazole 20 mg</td>
<td align="center">—</td>
<td>4</td>
<td/>
<td>−2.9</td>
<td>.0034</td>
</tr>
<tr>
<td/>
<td>Placebo</td>
<td align="center">—</td>
<td>4</td>
<td/>
<td>−1.8</td>
<td/>
</tr>
<tr>
<td>Yi 2008<sup><xref ref-type="bibr" rid="bibr27-0194599812436933">27</xref></sup>
</td>
<td>Esomeprazole 40 mg</td>
<td>6.0 (0.2)<sup><xref ref-type="table-fn" rid="table-fn10-0194599812436933">a</xref></sup>
</td>
<td>8</td>
<td>3.6 (0.2)<sup><xref ref-type="table-fn" rid="table-fn10-0194599812436933">a</xref></sup>
</td>
<td/>
<td>&lt;.01</td>
</tr>
<tr>
<td/>
<td>Placebo</td>
<td>5.8 (0.3)<sup><xref ref-type="table-fn" rid="table-fn10-0194599812436933">a</xref></sup>
</td>
<td>8</td>
<td>5.0 (0.2)<sup><xref ref-type="table-fn" rid="table-fn10-0194599812436933">a</xref></sup>
</td>
<td/>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn9-0194599812436933">
<p>Abbreviation: —, not provided.</p>
</fn>
<fn id="table-fn10-0194599812436933">
<label>a</label>
<p>Standard error of the mean.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The WPAI was used by Fass et al<sup><xref ref-type="bibr" rid="bibr23-0194599812436933">23</xref></sup> and Johnson et al<sup><xref ref-type="bibr" rid="bibr24-0194599812436933">24</xref>,<xref ref-type="bibr" rid="bibr25-0194599812436933">25</xref></sup> (<xref ref-type="table" rid="table6-0194599812436933"><bold>Table 6</bold></xref>). The WPAI is a validated 6-item questionnaire that assesses hours missed from work because of GERD-related sleep disturbance, hours missed from work for other reasons, hours actually worked, the degree (0-10 scale, with higher scores indicating greater impairment) that sleep disturbance secondary to GERD symptoms affected productivity while working, and the degree that sleep disturbance due to GERD symptoms affected regular activities.<sup><xref ref-type="bibr" rid="bibr25-0194599812436933">25</xref></sup> In all 3 studies, the degree to which sleep disturbance affected both work productivity and work hours lost per week, along with regular activities, was significantly more reduced in the drug group than in the placebo group.</p>
<table-wrap id="table6-0194599812436933" position="float">
<label>Table 6.</label>
<caption><p>Non-Polysomnography, Work Productivity and Activity Impairment: Impact of Treatment on Improvement in Work Productivity, Work Hours Lost, and Regular Activities</p></caption>
<graphic alternate-form-of="table6-0194599812436933" xlink:href="10.1177_0194599812436933-table6.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Primary Author</th>
<th align="center">Drug</th>
<th align="center">Interval to Outcome, wk</th>
<th align="center">Degree Sleep Disturbance Affected Work Productivity, <italic>P</italic> Value</th>
<th align="center">Work Hours Lost/wk/Patient, <italic>P</italic> Value</th>
<th align="center">Degree Sleep Disturbance Affected Regular Activities, <italic>P</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fass 2011<sup><xref ref-type="bibr" rid="bibr23-0194599812436933">23</xref></sup>
</td>
<td>Dexlansoprazole 30 mg</td>
<td>4</td>
<td>&lt;.01</td>
<td>.04</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>Johnson 2005<sup><xref ref-type="bibr" rid="bibr24-0194599812436933">24</xref>,<xref ref-type="table-fn" rid="table-fn11-0194599812436933">a</xref></sup>
</td>
<td>Esomeprazole 40 mg</td>
<td>4</td>
<td>&lt;.01</td>
<td>&lt;.01</td>
<td>&lt;.01</td>
</tr>
<tr>
<td/>
<td>Esomeprazole 20 mg</td>
<td>4</td>
<td>&lt;.01</td>
<td>&lt;.01</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>Johnson 2010<sup><xref ref-type="bibr" rid="bibr25-0194599812436933">25</xref>,<xref ref-type="table-fn" rid="table-fn11-0194599812436933">a</xref></sup>
</td>
<td>Esomeprazole 20 mg</td>
<td>4</td>
<td>&lt;.01</td>
<td>&lt;.01</td>
<td>&lt;.01</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn11-0194599812436933">
<label>a</label>
<p>Versus placebo.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The remaining non-polysomnography measures could be grouped as validated and nonvalidated measures (<xref ref-type="table" rid="table7-0194599812436933"><bold>Table 7</bold></xref>). All showed a statistically significant difference in terms of improvement comparing drug with placebo except 1 study by Orr et al.<sup><xref ref-type="bibr" rid="bibr26-0194599812436933">26</xref></sup></p>
<table-wrap id="table7-0194599812436933" position="float">
<label>Table 7.</label>
<caption><p>Other Validated and Nonvalidated Non-Polysomnography Outcomes Cited</p></caption>
<graphic alternate-form-of="table7-0194599812436933" xlink:href="10.1177_0194599812436933-table7.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Primary Author</th>
<th align="center">Interval to Outcome</th>
<th align="center">Duration, wk</th>
<th align="center">Validated</th>
<th align="center">Nonvalidated</th>
<th align="center"><italic>P</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bortolotti 2006<sup><xref ref-type="bibr" rid="bibr31-0194599812436933">31</xref>,<xref ref-type="table-fn" rid="table-fn13-0194599812436933">a</xref></sup>
</td>
<td>Recorded daily, averaged weekly</td>
<td>6</td>
<td/>
<td>Diary: weekly frequency of apnea attacks</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>Johnson 2005<sup><xref ref-type="bibr" rid="bibr24-0194599812436933">24</xref></sup>
</td>
<td>Recorded daily; the final 7 study days were compared</td>
<td>4</td>
<td/>
<td>Diary: % of patients with resolution and relief of GERD-associated sleep disturbances</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>Johnson 2010<sup><xref ref-type="bibr" rid="bibr25-0194599812436933">25</xref></sup>
</td>
<td>Recorded daily and compared over course of study; final 7 study days compared</td>
<td>4</td>
<td/>
<td>Diary: % of patients with relief of GERD-related sleep disturbance</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>Orr 2005<sup><xref ref-type="bibr" rid="bibr26-0194599812436933">26</xref></sup>
</td>
<td>Recorded daily, averaged weekly</td>
<td>2</td>
<td/>
<td>10-point VAS for subjective sleep quality</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>Orr 2007<sup><xref ref-type="bibr" rid="bibr20-0194599812436933">20</xref></sup>
</td>
<td>Recorded daily, averaged weekly</td>
<td>2</td>
<td/>
<td>100-point VAS for subjective sleep quality</td>
<td align="center">
<italic>NS</italic>
</td>
</tr>
<tr>
<td>Suurna 2008<sup><xref ref-type="bibr" rid="bibr21-0194599812436933">21</xref>,<xref ref-type="table-fn" rid="table-fn13-0194599812436933">a</xref></sup>
</td>
<td>Before and after each 2-week study period</td>
<td>4</td>
<td>Epworth Sleepiness Scale</td>
<td/>
<td>.04</td>
</tr>
<tr>
<td/>
<td>Before and after each 2-week study period</td>
<td>4</td>
<td>Functional Outcomes of Sleepiness Questionnaire</td>
<td/>
<td>.06</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn12-0194599812436933">
<p>Abbreviations: GERD, gastroesophageal reflux disease; <italic>NS</italic>, not significant; VAS, visual analog scale.</p>
</fn>
<fn id="table-fn13-0194599812436933">
<label>a</label>
<p>Study objective includes sleep-disordered breathing.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section11-0194599812436933">
<title>Quality Assessment</title>
<p>The Oxford Level of Evidence and Jadad scores are presented in <xref ref-type="table" rid="table8-0194599812436933"><bold>Table 8</bold></xref>. All studies received a 1b level. Three studies received a Jadad score of 5; 2 studies received a Jadad score of 1 or 2.</p>
<table-wrap id="table8-0194599812436933" position="float">
<label>Table 8.</label>
<caption><p>Quality Assessments</p></caption>
<graphic alternate-form-of="table8-0194599812436933" xlink:href="10.1177_0194599812436933-table8.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Primary Author</th>
<th align="center">Jadad</th>
<th align="center">Oxford Level of Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bortolotti 2006<sup><xref ref-type="bibr" rid="bibr31-0194599812436933">31</xref>,<xref ref-type="table-fn" rid="table-fn14-0194599812436933">a</xref></sup>
</td>
<td>3</td>
<td>1b</td>
</tr>
<tr>
<td>Fass 2011<sup><xref ref-type="bibr" rid="bibr23-0194599812436933">23</xref></sup>
</td>
<td>5</td>
<td>1b</td>
</tr>
<tr>
<td>Johnson 2005<sup><xref ref-type="bibr" rid="bibr24-0194599812436933">24</xref></sup>
</td>
<td>5</td>
<td>1b</td>
</tr>
<tr>
<td>Johnson 2010<sup><xref ref-type="bibr" rid="bibr25-0194599812436933">25</xref></sup>
</td>
<td>5</td>
<td>1b</td>
</tr>
<tr>
<td>Orr 2005<sup><xref ref-type="bibr" rid="bibr26-0194599812436933">26</xref></sup>
</td>
<td>3</td>
<td>1b</td>
</tr>
<tr>
<td>Orr 2007<sup><xref ref-type="bibr" rid="bibr20-0194599812436933">20</xref></sup>
</td>
<td>2</td>
<td>1b</td>
</tr>
<tr>
<td>Suurna 2008<sup><xref ref-type="bibr" rid="bibr21-0194599812436933">21</xref>,<xref ref-type="table-fn" rid="table-fn14-0194599812436933">a</xref></sup>
</td>
<td>4</td>
<td>1b</td>
</tr>
<tr>
<td>Yi 2008<sup><xref ref-type="bibr" rid="bibr27-0194599812436933">27</xref></sup>
</td>
<td>1</td>
<td>1b</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn14-0194599812436933">
<label>a</label>
<p>Study objective includes sleep-disordered breathing.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="section12-0194599812436933" sec-type="discussion">
<title>Discussion</title>
<p>The main SR conclusion is that the use of PPIs improves non-polysomnography sleep disturbance–related outcomes for patients with esophageal reflux disease, with 7 of the 8 studies documenting a statistically significant outcome improvement for drug treatment superiority over placebo. Five of these 7 studies used validated non-polysomnography measures such as the PSQI, WPAI, and ESS.</p>
<p>Of the 3 studies that used the PSQI and WPAI (Fass et al,<sup><xref ref-type="bibr" rid="bibr23-0194599812436933">23</xref></sup> Johnson et al<sup><xref ref-type="bibr" rid="bibr24-0194599812436933">24</xref>,<xref ref-type="bibr" rid="bibr25-0194599812436933">25</xref></sup>), all were given a Jadad score of 5 as well as a 1b Oxford Level of Evidence. All 3 of these high-quality RCTs showed a highly significant statistical PPI treatment-related improvement. A fourth study, by Yi et al,<sup><xref ref-type="bibr" rid="bibr27-0194599812436933">27</xref></sup> which also looked at PSQI, was given the lowest Jadad score of 1 and a 1b Oxford Level of Evidence. Although a lower quality RCT, these authors again demonstrated a statistically significant improvement in the PPI-related outcomes.</p>
<p>The 1 study that did not show statistical improvement in non-polysomnography sleep disturbance–related outcomes, Orr et al,<sup><xref ref-type="bibr" rid="bibr20-0194599812436933">20</xref></sup> concluded that powerful acid suppression, in this case with esomeprazole 40 mg bid, during sleep decreased total reflux events. However, treatment also tended to increase the trend for more nonacidic reflux events as documented on multichannel intraluminal impedance used in addition to pH monitoring. The authors felt nonacidic reflux events were a possible contribution to poorer sleep quality and one that should be verified in future investigations. This was the only study that gave patients a provocative meal 1 hour prior to “lights out.” The authors explained that this was done to raise the baseline occurrence of reflux events to facilitate the assessment of a treatment effect. It is interesting to note that the same authors performed an earlier similar study<sup><xref ref-type="bibr" rid="bibr26-0194599812436933">26</xref></sup> using rabeprazole 20 mg bid, pH monitoring, and a VAS. A provocative meal was not given. They concluded that pharmacological treatments for gastroesophageal reflux improved subjective but not objective measures of sleep. Study differences included medications, measures of intraesophageal reflux, the use of a provocative meal, and the range of scale for VAS.</p>
<p>The wide variability in treatments as well as outcome measures limited a more complete detailed comparison and/or aggregation of study findings. Only 4 studies chose the same PPI for investigation. Five studies allowed the use of rescue antacids, and 2 allowed the use of additional medication that could affect sleep. These included the 3 “best” studies (Fass et al<sup><xref ref-type="bibr" rid="bibr23-0194599812436933">23</xref></sup> and Johnson et al<sup><xref ref-type="bibr" rid="bibr24-0194599812436933">24</xref>,<xref ref-type="bibr" rid="bibr25-0194599812436933">25</xref></sup>), which were also the 3 largest studies. Although the use of rescue antacids appears to be common among studies and the amount allowed is usually defined, the overall impact of these and other allowed additional medications on outcomes is unclear. Three studies did not report BMI, an important factor for both reflux disease and sleep disturbance. The gender distribution of study participants varied widely.</p>
<p>All 8 studies included an objective to assess the effect of PPI on sleep, with 5 of the 8 specifically studying sleep-related disturbances. Orr et al<sup><xref ref-type="bibr" rid="bibr26-0194599812436933">26</xref></sup> and Yi et al<sup><xref ref-type="bibr" rid="bibr27-0194599812436933">27</xref></sup> both studied patient populations with baseline mean PSQI greater than 5, which is considered poor quality sleep. Orr et al<sup><xref ref-type="bibr" rid="bibr20-0194599812436933">20</xref></sup> patient population mean sleep efficiency was below 85%.</p>
<p>Polysomnography is widely considered the gold standard for sleep-disordered breathing. Both studies (whose stated objectives were to study sleep-disordered breathing) did not use PSG for measured outcomes. Polysomnography was used as a sleep outcome in only 2 studies, Orr et al<sup><xref ref-type="bibr" rid="bibr26-0194599812436933">26</xref></sup> and Orr et al,<sup><xref ref-type="bibr" rid="bibr20-0194599812436933">20</xref></sup> both of which were looking at sleep disturbance in GERD patients. Of these 2 studies, only Orr et al<sup><xref ref-type="bibr" rid="bibr26-0194599812436933">26</xref></sup> excluded patients with sleep-disordered breathing. Both reported no significant difference between placebo and drug in measured outcomes. The duration of each was only 1 week of treatment prior to PSG evaluation. Although beyond the scope of this study, a brief review of the literature did find 3 non-RCTs that used PSG (specifically AHI) outcomes for treatment periods ranging from 1 to 12 months. Orr et al<sup><xref ref-type="bibr" rid="bibr28-0194599812436933">28</xref></sup> and Steward<sup><xref ref-type="bibr" rid="bibr29-0194599812436933">29</xref></sup> both found no significant difference between placebo and drug for AHI as a measured outcome. Friedman et al<sup><xref ref-type="bibr" rid="bibr30-0194599812436933">30</xref></sup> did find a significant difference (<italic>P</italic> = .006) with a treatment interval up to 12 months.</p>
<p>A number of other studies have reported on the use of PSG to validate subjective sleep reports. Although subjective estimates and objective measures of sleep differ in actual amount, they are often strongly and positively correlated. Postsleep questionnaires yield more accurate subjective estimates that are more strongly correlated with PSG findings. The PSQI asks for a global estimate spanning 1 month and is not sensitive to daily variability.<sup><xref ref-type="bibr" rid="bibr22-0194599812436933">22</xref></sup> The WPAI also looks at longer intervals of time.</p>
<p>Finally, although the PSQI showed statistically significant improvement, this was not consistently reflected in a return of outcome measures to a “normal” range, a PSQI &lt;5. However, in all 3 studies that also looked at the WPAI, the impact of treatment with PPI was found to result in a statistically significant improvement in the degree that sleep disturbance affected work productivity and work hours lost per week, as well as the degree sleep disturbance affected regular activities. The authors also calculated a projected economic benefit that was greater than that of the placebo group.</p>
</sec>
<sec id="section13-0194599812436933" sec-type="conclusions">
<title>Conclusion</title>
<p>The existing evidence supports the use of PPI medications as a treatment to improve esophageal reflux disease symptoms and associated quality-of-life sleep disturbance-related outcomes. This conclusion appears to be robust based on reviewing all 8 included randomized placebo-controlled trials as well as the subgroup of the 3 highest quality studies published to date. Although the improvements are likely secondary gains from reduction or elimination of nocturnal GERD symptoms, further research appears warranted to evaluate PPI treatment impact on polysomnography outcomes, as well as to examine the relationship of polysomnography vs non-polysomnography outcomes, for GERD patients with sleep disturbance and sleep-disordered breathing.</p>
</sec>
<sec id="section14-0194599812436933">
<title>Author Contributions</title>
<p><bold>Elliot Regenbogen</bold>, primarily responsible for SR protocol conception and design, acquisition of data, analysis and interpretation of data, drafting the article, and approving the final version; <bold>Alex Helkin</bold>, acquisition of data, analysis, interpretation of data, and approving the final version; <bold>Rachel Georgopoulos</bold>, acquisition of data, analysis, interpretation of data, and approving the final version; <bold>Tajender Vasu</bold>, acquisition of data, analysis, interpretation of data, and approving the final version; <bold>A. Laurie W. Shroyer</bold>, SR protocol design, data analysis, interpretation of data, revising the manuscript, and approving the final version.</p>
</sec>
<sec id="section15-0194599812436933">
<title>Disclosures</title>
<p><bold>Competing interests:</bold> None.</p>
<p><bold>Sponsorships:</bold> None.</p>
<p><bold>Funding source:</bold> Work was supported in part by an AAO-HNS Cochrane Scholars Grant to attend the 18th Cochrane Colloquium for training, discussion workshops, and full scientific program. In return for a travel grant to attend the meeting, the attendees agreed to submit a systematic review to <italic>Otolaryngology–Head and Neck Surgery</italic>.</p>
</sec>
</body>
<back>
<ack>
<p>As a lead Stony Brook University School of Medicine (SBU SOM) reference librarian, the authors express their sincerest thanks to Colleen M. Kenefick, MLS, AHIP, for her expertise in database research. As part of the SBU SOM Department of Surgery administrative staff, appreciation is extended to Jacqueline Nicoletto for her proofreading, table reformatting, and other SR project-related support.</p>
</ack>
<fn-group>
<fn fn-type="presented-at">
<p>Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0194599812436933">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Heidelbaugh</surname><given-names>JJ</given-names></name>
<name><surname>Goldberg</surname><given-names>KL</given-names></name>
<name><surname>Inadomi</surname><given-names>JM</given-names></name>
</person-group>. <article-title>Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk in PPI</article-title>. <source>Am J Gastroenterol</source>. <year>2009</year>;<volume>104</volume>:<fpage>S27</fpage>-<lpage>S32</lpage>.</citation>
</ref>
<ref id="bibr2-0194599812436933">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>DeVault</surname><given-names>KR</given-names></name>
<name><surname>Castell</surname><given-names>DO</given-names></name>
</person-group>. <article-title>Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease</article-title>. <source>Am J Gastroenterol</source>. <year>2005</year>;<volume>100</volume>:<fpage>90</fpage>-<lpage>100</lpage>.</citation>
</ref>
<ref id="bibr3-0194599812436933">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pasricha</surname><given-names>PJ</given-names></name>
</person-group>. <article-title>Effect of sleep on gastroesophageal physiology and airway protective mechanisms</article-title>. <source>Am J Med</source>. <year>2003</year>;<volume>115</volume>(<supplement>suppl 3A</supplement>):<fpage>114S</fpage>-<lpage>118S</lpage>.</citation>
</ref>
<ref id="bibr4-0194599812436933">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Green</surname><given-names>BT</given-names></name>
<name><surname>Broughton</surname><given-names>WA</given-names></name>
<name><surname>O’Connor</surname><given-names>B</given-names></name>
</person-group>. <article-title>Marked improvement in nocturnal gastroesophageal reflux in a large cohort of patients with obstructive sleep apnea treated with continuous positive airway pressure</article-title>. <source>Arch Intern Med</source>. <year>2003</year>;<volume>163</volume>:<fpage>41</fpage>-<lpage>45</lpage>.</citation>
</ref>
<ref id="bibr5-0194599812436933">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lagergren</surname><given-names>J</given-names></name>
<name><surname>Bergstrom</surname><given-names>R</given-names></name>
<name><surname>Lindgren</surname><given-names>A</given-names></name>
<name><surname>Nyren</surname><given-names>O</given-names></name>
</person-group>. <article-title>Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma</article-title>. <source>N Engl J Med</source>. <year>1999</year>;<volume>340</volume>:<fpage>825</fpage>-<lpage>831</lpage>.</citation>
</ref>
<ref id="bibr6-0194599812436933">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Orr</surname><given-names>WC</given-names></name>
<name><surname>Lackey</surname><given-names>C</given-names></name>
<name><surname>Robinson</surname><given-names>MG</given-names></name>
<name><surname>Johnson</surname><given-names>LF</given-names></name>
<name><surname>Welsh</surname><given-names>JD</given-names></name>
</person-group>. <article-title>Esophageal acid clearance during sleep in patients with Barrett’s esophagus</article-title>. <source>Dig Dis Sci</source>. <year>1988</year>;<volume>33</volume>:<fpage>654</fpage>-<lpage>659</lpage>.</citation>
</ref>
<ref id="bibr7-0194599812436933">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Revicki</surname><given-names>DA</given-names></name>
<name><surname>Wood</surname><given-names>M</given-names></name>
<name><surname>Maton</surname><given-names>PN</given-names></name>
<name><surname>Sorensen</surname><given-names>S</given-names></name>
</person-group>. <article-title>The impact of gastroesophageal reflux disease on health-related quality of life</article-title>. <source>Am J Med</source>. <year>1998</year>;<volume>104</volume>:<fpage>252</fpage>-<lpage>258</lpage>.</citation>
</ref>
<ref id="bibr8-0194599812436933">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Khoury</surname><given-names>RM</given-names></name>
<name><surname>Camacho-Lobato</surname><given-names>L</given-names></name>
<name><surname>Katz</surname><given-names>PO</given-names></name>
<name><surname>Mohiuddin</surname><given-names>MA</given-names></name>
<name><surname>Castell</surname><given-names>DO</given-names></name>
</person-group>. <article-title>Influence of spontaneous sleep positions on nighttime recumbent reflux in patients with gastroesophageal reflux disease</article-title>. <source>Am J Gastroenterol</source>. <year>1999</year>;<volume>94</volume>:<fpage>2069</fpage>-<lpage>2073</lpage>.</citation>
</ref>
<ref id="bibr9-0194599812436933">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ing</surname><given-names>AJ</given-names></name>
<name><surname>Ngu</surname><given-names>MC</given-names></name>
<name><surname>Breslin</surname><given-names>AB</given-names></name>
</person-group>. <article-title>Obstructive sleep apnea and gastroesophageal reflux</article-title>. <source>Am J Med</source>. <year>2000</year>;<volume>108</volume>(<supplement>suppl 4A</supplement>):<fpage>120S</fpage>-<lpage>125S</lpage>.</citation>
</ref>
<ref id="bibr10-0194599812436933">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Orr</surname><given-names>WC</given-names></name>
</person-group>. <article-title>Sleep-related breathing disorders: is it all about apnea?</article-title> <source>Chest</source>. <year>2002</year>;<volume>121</volume>:<fpage>8</fpage>-<lpage>11</lpage>.</citation>
</ref>
<ref id="bibr11-0194599812436933">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Janson</surname><given-names>C</given-names></name>
<name><surname>Gislason</surname><given-names>T</given-names></name>
<name><surname>De Backer</surname><given-names>W</given-names></name>
<etal/>
</person-group>. <article-title>Daytime sleepiness, snoring and gastro-esophageal reflux amongst young adults in three European countries</article-title>. <source>J Intern Med</source>. <year>1995</year>;<volume>237</volume>:<fpage>277</fpage>-<lpage>285</lpage>.</citation>
</ref>
<ref id="bibr12-0194599812436933">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Penzel</surname><given-names>T</given-names></name>
<name><surname>Becker</surname><given-names>HF</given-names></name>
<name><surname>Brandenburg</surname><given-names>T</given-names></name>
<name><surname>Labunski</surname><given-names>T</given-names></name>
<name><surname>Pankow</surname><given-names>W</given-names></name>
<name><surname>Peter</surname><given-names>JH</given-names></name>
</person-group>. <article-title>Arousal in patients with gastro-esophageal reflux and sleep apnea</article-title>. <source>Eur Respir J</source>. <year>1999</year>;<volume>14</volume>:<fpage>1266</fpage>-<lpage>1270</lpage>.</citation>
</ref>
<ref id="bibr13-0194599812436933">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gislason</surname><given-names>T</given-names></name>
<name><surname>Janson</surname><given-names>C</given-names></name>
<name><surname>Vermeire</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>Respiratory symptoms and nocturnal gastroesophageal reflux: a population-based study of young adults in three European countries</article-title>. <source>Chest</source>. <year>2002</year>;<volume>121</volume>:<fpage>158</fpage>-<lpage>163</lpage>.</citation>
</ref>
<ref id="bibr14-0194599812436933">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Janson</surname><given-names>C</given-names></name>
<name><surname>Gislason</surname><given-names>T</given-names></name>
<name><surname>De Backer</surname><given-names>W</given-names></name>
<etal/>
</person-group>. <article-title>Prevalence of sleep disturbances among young adults in three European countries</article-title>. <source>Sleep</source>. <year>1995</year>;<volume>18</volume>:<fpage>589</fpage>-<lpage>597</lpage>.</citation>
</ref>
<ref id="bibr15-0194599812436933">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Suganuma</surname><given-names>N</given-names></name>
<name><surname>Shigedo</surname><given-names>Y</given-names></name>
<name><surname>Adachi</surname><given-names>H</given-names></name>
<etal/>
</person-group>. <article-title>Association of gastroesophageal reflux disease with weight gain and apnea, and their disturbance on sleep</article-title>. <source>Psychiatry Clin Neurosci</source>. <year>2001</year>;<volume>55</volume>:<fpage>255</fpage>-<lpage>256</lpage>.</citation>
</ref>
<ref id="bibr16-0194599812436933">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Leodolter</surname><given-names>A</given-names></name>
<name><surname>Kulig</surname><given-names>M</given-names></name>
<name><surname>Nocon</surname><given-names>M</given-names></name>
<name><surname>Vieth</surname><given-names>M</given-names></name>
<name><surname>Lindner</surname><given-names>D</given-names></name>
<name><surname>Labenz</surname><given-names>J.</given-names></name>
</person-group> <article-title>Esomeprazole therapy improves sleep disorders in patients with gastroesophageal reflux disease (GERD): a report from the ProGERD study</article-title>. <source>Gastroenterology</source>. <year>2003</year>;<volume>124</volume>(<supplement>suppl 1</supplement>):<fpage>A-226</fpage>.</citation>
</ref>
<ref id="bibr17-0194599812436933">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shaker</surname><given-names>R</given-names></name>
<name><surname>Castell</surname><given-names>DO</given-names></name>
<name><surname>Schoenfeld</surname><given-names>PS</given-names></name>
<name><surname>Spechler</surname><given-names>SJ</given-names></name>
</person-group>. <article-title>Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association</article-title>. <source>Am J Gastroenterol</source>. <year>2003</year>;<volume>98</volume>:<fpage>1487</fpage>-<lpage>1493</lpage>.</citation>
</ref>
<ref id="bibr18-0194599812436933">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jadad</surname><given-names>AR</given-names></name>
<name><surname>Moore</surname><given-names>RA</given-names></name>
<name><surname>Carroll</surname><given-names>D</given-names></name>
<etal/>
</person-group>. <article-title>Assessing the quality of reports of randomized clinical trials: is blinding necessary?</article-title> <source>Control Clin Trials</source>. <year>1996</year>;<volume>17</volume>:<fpage>1</fpage>-<lpage>12</lpage>.</citation>
</ref>
<ref id="bibr19-0194599812436933">
<label>19.</label>
<citation citation-type="web">
<collab>OCEBM Levels of Evidence Working Group. The Oxford</collab> <year>2011</year> <article-title>Levels of Evidence. Oxford Centre for Evidence-Based Medicine</article-title>. <comment><ext-link ext-link-type="uri" xlink:href="http://www.cebm.net/index.aspx?o=5653">http://www.cebm.net/index.aspx?o=5653</ext-link></comment>. <access-date>Accessed November 29, 2011</access-date>.</citation>
</ref>
<ref id="bibr20-0194599812436933">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Orr</surname><given-names>WC</given-names></name>
<name><surname>Craddock</surname><given-names>A</given-names></name>
<name><surname>Goodrich</surname><given-names>S</given-names></name>
</person-group>. <article-title>Acidic and non-acidic reflux during sleep under conditions of powerful acid suppression</article-title>. <source>Chest</source>. <year>2007</year>;<volume>131</volume>:<fpage>460</fpage>-<lpage>465</lpage>.</citation>
</ref>
<ref id="bibr21-0194599812436933">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Suurna</surname><given-names>MV</given-names></name>
<name><surname>Welge</surname><given-names>J</given-names></name>
<name><surname>Surdulescu</surname><given-names>V</given-names></name>
<name><surname>Kushner</surname><given-names>J</given-names></name>
<name><surname>Steward</surname><given-names>DL</given-names></name>
</person-group>. <article-title>Randomized placebo-controlled trial of pantoprazole for daytime sleepiness in GERD and obstructive sleep disordered breathing</article-title>. <source>Otolaryngol Head Neck Surg</source>. <year>2008</year>;<volume>139</volume>:<fpage>286</fpage>-<lpage>290</lpage>.</citation>
</ref>
<ref id="bibr22-0194599812436933">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Buysse</surname><given-names>DJ</given-names></name>
<name><surname>Reynolds</surname><given-names>CF</given-names></name>
<name><surname>Monk</surname><given-names>TH</given-names></name>
<name><surname>Berman</surname><given-names>SR</given-names></name>
<name><surname>Kupfer</surname><given-names>DJ</given-names></name>
</person-group>. <article-title>The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research</article-title>. <source>Psychiatry Res</source>. <year>1989</year>;<volume>28</volume>:<fpage>193</fpage>-<lpage>213</lpage>.</citation>
</ref>
<ref id="bibr23-0194599812436933">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fass</surname><given-names>R</given-names></name>
<name><surname>Johnson</surname><given-names>DA</given-names></name>
<name><surname>Orr</surname><given-names>WC</given-names></name>
<etal/>
</person-group>. <article-title>The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD</article-title>. <source>Am J Gastroenterol</source>. <year>2011</year>;<volume>106</volume>:<fpage>421</fpage>-<lpage>431</lpage>.</citation>
</ref>
<ref id="bibr24-0194599812436933">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Johnson</surname><given-names>DA</given-names></name>
<name><surname>Orr</surname><given-names>WC</given-names></name>
<name><surname>Crawley</surname><given-names>JA</given-names></name>
<etal/>
</person-group>. <article-title>Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: a randomized, placebo-controlled trial</article-title>. <source>Am J Gastroenterol</source>. <year>2005</year>;<volume>100</volume>:<fpage>1914</fpage>-<lpage>1922</lpage>.</citation>
</ref>
<ref id="bibr25-0194599812436933">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Johnson</surname><given-names>D</given-names></name>
<name><surname>Crawley</surname><given-names>JA</given-names></name>
<name><surname>Hwang</surname><given-names>C</given-names></name>
<name><surname>Brown</surname><given-names>K</given-names></name>
</person-group>. <article-title>Clinical trial: esomeprazole for moderate-to-severe nighttime heartburn and gastro-esophageal reflux disease-related sleep disturbances</article-title>. <source>Aliment Pharmacol Ther</source>. <year>2010</year>;<volume>32</volume>:<fpage>182</fpage>-<lpage>190</lpage>.</citation>
</ref>
<ref id="bibr26-0194599812436933">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Orr</surname><given-names>WC</given-names></name>
<name><surname>Goodrich</surname><given-names>S</given-names></name>
<name><surname>Robert</surname><given-names>J</given-names></name>
</person-group>. <article-title>The effect of acid suppression on sleep patterns and sleep-related gastro-esophageal reflux</article-title>. <source>Aliment Pharmacol Ther</source>. <year>2005</year>;<volume>21</volume>:<fpage>103</fpage>-<lpage>108</lpage>.</citation>
</ref>
<ref id="bibr27-0194599812436933">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yi</surname><given-names>CH</given-names></name>
<name><surname>Chen</surname><given-names>CL</given-names></name>
<name><surname>Kuo</surname><given-names>TB</given-names></name>
<name><surname>Yang</surname><given-names>CC</given-names></name>
</person-group>. <article-title>The effect of acid suppression on sleep and cardiac autonomic regulation in GERD</article-title>. <source>Hepatogastroenterology</source>. <year>2008</year>;<volume>55</volume>:<fpage>1649</fpage>-<lpage>1652</lpage>.</citation>
</ref>
<ref id="bibr28-0194599812436933">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Orr</surname><given-names>WC</given-names></name>
<name><surname>Robert</surname><given-names>JJ</given-names></name>
<name><surname>Houck</surname><given-names>JR</given-names></name>
<name><surname>Giddens</surname><given-names>CL</given-names></name>
<name><surname>Tawk</surname><given-names>MM</given-names></name>
</person-group>. <article-title>The effect of acid suppression on upper airway anatomy and obstruction in patients with sleep apnea and gastroesophageal reflux disease</article-title>. <source>J Clin Sleep Med</source>. <year>2009</year>;<volume>5</volume>:<fpage>330</fpage>-<lpage>334</lpage>.</citation>
</ref>
<ref id="bibr29-0194599812436933">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Steward</surname><given-names>DL</given-names></name>
</person-group>. <article-title>Pantoprazole for sleepiness associated with acid reflux and obstructive sleep disordered breathing</article-title>. <source>Laryngoscope</source>. <year>2004</year>;<volume>114</volume>:<fpage>1525</fpage>-<lpage>1528</lpage>.</citation>
</ref>
<ref id="bibr30-0194599812436933">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Friedman</surname><given-names>M</given-names></name>
<name><surname>Gurpinar</surname><given-names>B</given-names></name>
<name><surname>Lin</surname><given-names>HC</given-names></name>
<name><surname>Schalch</surname><given-names>P</given-names></name>
<name><surname>Joseph</surname><given-names>NJ</given-names></name>
</person-group>. <article-title>Impact of treatment of gastroesophageal reflux on obstructive sleep apnea-hypopnea syndrome</article-title>. <source>Ann Otol Rhinol Laryngol</source>. <year>2007</year>;<volume>116</volume>:<fpage>805</fpage>-<lpage>811</lpage>.</citation>
</ref>
<ref id="bibr31-0194599812436933">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bortolotti</surname><given-names>M</given-names></name>
<name><surname>Gentilini</surname><given-names>L</given-names></name>
<name><surname>Morselli</surname><given-names>C</given-names></name>
<name><surname>Giovannini</surname><given-names>M</given-names></name>
</person-group>. <article-title>Obstructive sleep apnea is improved by a prolonged treatment of gastrooesophageal reflux with omeprazole</article-title>. <source>Dig Liver Dis</source>. <year>2006</year>;<volume>38</volume>:<fpage>78</fpage>-<lpage>81</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>